IGN Stock Overview
Provides genetic diagnostic solutions in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Inno-Gene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.29 |
| 52 Week High | zł5.60 |
| 52 Week Low | zł1.65 |
| Beta | 1.13 |
| 11 Month Change | -20.15% |
| 3 Month Change | 7.87% |
| 1 Year Change | 2.81% |
| 33 Year Change | -64.43% |
| 5 Year Change | 58.17% |
| Change since IPO | -23.49% |
Recent News & Updates
Recent updates
Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today
Jul 25
Here's Why We Think Inno-Gene (WSE:IGN) Is Well Worth Watching
Apr 05Here's Why I Think Inno-Gene (WSE:IGN) Is An Interesting Stock
Dec 28Should You Be Adding Inno-Gene (WSE:IGN) To Your Watchlist Today?
Aug 28We Wouldn't Rely On Inno-Gene's (WSE:IGN) Statutory Earnings As A Guide
Feb 17
Shareholder Returns
| IGN | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | -11.8% | -7.4% | -3.1% |
| 1Y | 2.8% | -17.7% | -1.7% |
Return vs Industry: IGN exceeded the Polish Life Sciences industry which returned -17.7% over the past year.
Return vs Market: IGN exceeded the Polish Market which returned -1.7% over the past year.
Price Volatility
| IGN volatility | |
|---|---|
| IGN Average Weekly Movement | 21.2% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: IGN's share price has been volatile over the past 3 months compared to the Polish market.
Volatility Over Time: IGN's weekly volatility has increased from 15% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 8 | n/a | www.inno-gene.pl |
Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of HPV-dependent solid tumors.
Inno-Gene S.A. Fundamentals Summary
| IGN fundamental statistics | |
|---|---|
| Market cap | zł114.18m |
| Earnings (TTM) | -zł6.22m |
| Revenue (TTM) | zł373.00k |
296.2x
P/S Ratio-17.7x
P/E RatioIs IGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGN income statement (TTM) | |
|---|---|
| Revenue | zł373.00k |
| Cost of Revenue | zł683.00k |
| Gross Profit | -zł310.00k |
| Other Expenses | zł5.92m |
| Earnings | -zł6.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | -83.11% |
| Net Profit Margin | -1,668.90% |
| Debt/Equity Ratio | 1.1% |
How did IGN perform over the long term?
See historical performance and comparison